Arcutis Biotherapeutics (ARQT)

Financial Performance

Arcutis Biotherapeutics has shown strong growth in its financial performance. The company's revenue of $44.8M, up by 45% from the previous quarter and 230.9% year over year, indicates a solid trend of increasing sales. Their gross profit at $39.3M is also on an upward trajectory, with a rise of 43.3% from the previous quarter and a significant increase of 254.2% YoY. However, their operating income is negative at -$39.1M but it improved by 22% QoQ and by 36.1% YoY which shows that they are effectively managing their expenses to improve profitability over time.

Stock Price

The stock price for Arcutis Biotherapeutics has been performing well with an increase of 27.8% in the last month, and an impressive jump of 420.1% YoY indicating strong investor confidence in the company's prospects despite its negative PE ratio (-7.60) and EPS (-1.67). The RSI value stands at around mid-range (66), suggesting that the stock is neither oversold nor overbought while the stock's price being above its 200-day moving average ($9.75) implies positive momentum.

Alternative Data Signals

The alternative data signals present mixed results for Arcutis Biotherapeutics' future prospects as web traffic numbers have increased MoM but decreased YoY indicating inconsistent interest online towards the company.The lack of job openings could suggest cost-cutting measures or simply no need for expansion currently.Employee sentiment regarding business outlook appears neutral which may not be enough to drive significant changes in stock performance.Finally,the social media followers count shows growth on Twitter but a slight decline on Facebook,indicating mixed sentiment among the company's social media audience.

Conclusion

In conclusion,the analysis of Arcutis Biotherapeutics' stock is neutral to slightly bullish.The company's strong revenue and gross profit growth,along with its improving operating income and positive stock price momentum are promising signs.However,the negative PE ratio,EPS and mixed alternative data signals suggest some caution is warranted.

Note: This AI Stock Analysis is based on data as of December 14. Our members can refresh and get access to an up-to-date AI stock analysis.

Sign up

Based on a combination of financial analysis, technical indicators, and insights from alternative data, we predict that the stock price of Arcutis Biotherapeutics (ARQT), currently trading at $12.68, will... Sign up to access price prediction.

Disclaimer:
This prediction is provided for informational purposes only and does not constitute financial advice. Market conditions are subject to change, and past performance is not indicative of future results. Please conduct your own research or consult a professional before making investment decisions.